Diebold Nixdorf
DBD | NYSE
$63.37
+$0.17 (+0.27%)
At close: Sep 21, 2026, 4:00 PM ET
$63.40
+$0.03 (+0.05%)
After-hours:
Sep 21, 2026, 5:24 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 3.81B | 3.75B | 3.76B | 3.46B | 3.91B | 3.9B |
Cost of Revenue | 2.8B | 2.83B | 2.88B | 2.7B | 2.86B | 2.87B |
Gross Profit | 1B | 920M | 876.2M | 757.3M | 1.04B | 1.04B |
Operating Income | 334.6M | 182.1M | 86.9M | -211.7M | 137.1M | 24M |
Interest Income | 8.9M | 12.3M | 13M | 10M | 6.1M | 6.8M |
Pretax Income | 121.6M | 49.8M | 1.45B | -436.4M | -50.4M | -268.8M |
Net Income | 94.6M | -16.5M | 1.38B | -581.4M | -78.8M | -269.1M |
Selling & General & Admin | 585M | 643.6M | n/a | 741.6M | 775.6M | 858.6M |
Research & Development | 83.8M | 93.6M | 110.9M | 120.7M | 126.3M | 133.4M |
Other Expenses | n/a | 700K | 678.4M | 106.7M | 4.4M | 19M |
Operating Expenses | 668.8M | 737.9M | 789.3M | 969M | 906.3M | 1.01B |
Interest Expense | 85.7M | 155.3M | 246.2M | 199.2M | 195.3M | 273.4M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.47B | 3.57B | 3.67B | 3.67B | 3.77B | 3.88B |
Income Tax Expense | 24.1M | 64.3M | 75.7M | 149.2M | 27.7M | -1M |
Shares Outstanding (Basic) | 36.8M | 37.6M | 64.36M | 79M | 78.3M | 77.6M |
Shares Outstanding (Diluted) | 37.2M | 37.6M | 64.36M | 79M | 78.3M | 77.6M |
EPS (Basic) | 2.57 | -0.44 | 21.38 | -7.44 | -1 | -3.47 |
EPS (Diluted) | 2.54 | -0.44 | 21.38 | -7.44 | -1 | -3.47 |
EBITDA | 334.8M | 334.9M | 275M | -113.4M | 293.7M | 177.7M |
EBIT | 207.3M | 202.6M | 148.6M | -239.4M | 144.6M | -2.7M |
Depreciation & Amortization | 127.5M | 132.3M | 126.4M | 126M | 149.1M | 180.4M |
Add to Watchlist
Select watchlists to add or remove DBD